Laboratory for Advanced Medicine to Present at 2018 Biotech Showcase

Wednesday, January 3, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

IRVINE, Calif., Jan. 3, 2018 /PRNewswire/ -- Laboratory for Advanced Medicine (LAM), a clinical-stage biopharmaceutical

company focused on developing cutting-edge non-invasive, non-toxic technologies for early diagnosis and intervention of various cancers, today announced that the Company's founder and chairman, Shu Li, will present at the
10th Annual Biotech Showcase™, taking place on Jan. 8 through 10, 2018, in San Francisco, Calif.

Dr. Li will present an overview of LAM's business, technology and strategic growth objectives and will also be available to participate in one-on-one meetings with members of the financial and financial media communities. The details of his presentation are as follows:

Date: Tuesday, Jan. 9, 2018Time: 3:00 p.m. PST (6:00 p.m. EST)Location: Franciscan - D (Ballroom level), Hilton San Francisco Union Square (333 O'Farrell St., San Francisco, Calif., 94102)

The largest international biotech investor conference in the world, Biotech Showcase brings together life sciences decision-makers and investors from across the globe to collaborate and discuss industry trends through panels, workshops and fireside chats. Additional information and registration can be found here:

To schedule a meeting with Dr. Li during the Biotech Showcase, contact

About Laboratory for Advanced MedicineLAM is a clinical-stage biopharmaceutical company focused on developing cutting-edge non-invasive, non-toxic technologies for early diagnosis and intervention, possibly years before symptoms arise. LAM is dedicated to building and growing world-class technologies still in development from the laboratory to the clinic. LAM operates scientifically, ethically and efficiently to bring these cutting-edge technologies into the mainstream.

LAM is headquartered in the United States with offices in California, Texas and Indiana. LAM is a multinational business with collaborations in both the United States and China, including leading scientists, physicians, research institutions and business leaders. LAM strives to combine the experiences of these innovators and achievers to provide the healthiest and safest diagnostic technologies to everyone.

LAM has CLIA- and CAP-certified laboratories, third-party laboratories and cGMP facilities all working toward the endeavor of bringing these first-class technologies into the medical community.

About IvyGene® The IvyGene test is owned by the Laboratory for Advanced Medicine, Inc. IvyGene is a blood test for the presence of cancer and quantification of ctDNA presence. IvyGene leverages studies using advanced DNA sequencing methods to detect the DNA methylation pattern of cell-free DNA in blood. The sequence, along with the pattern of methylated DNA, is consistent with cancer presence.

Unlike many genetic tests that use DNA to determine the propensity or possibility of developing cancer over time, the IvyGene test identifies DNA methylation patterns consistent with actual disease presence and quantification of ctDNA presence at the time of testing.

Cision View original content:

SOURCE Laboratory for Advanced Medicine

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store